Relative dose intensity: Improving cancer treatment and outcomes

Oncology Nursing Forum

Volumn 32, Issue 4, 2005, Pages 757-764

  Lenhart, Cheryl ^a,b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b Wyeth Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; NEOPLASM; NURSING; PATIENT COMPLIANCE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33645852590     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.757-764     Document Type: Article

References (22)

1. Abels, R.I. (1992). Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematologica, 87(Suppl. 1), 4-11.
2. Bonadonna, G.. Valagussa, P., Moliterni, A.. Zambetti, M, & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate. and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906.
3. Budman, D.R., Berry, D.A., Cirrincione, CT., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205-1211.
4. Cairo, M.S. (2000). Dose reductions and delays: Limitations of myelosuppressive chemotherapy. Oncology, 14(9, Suppl. 8), 21-31.
5. Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., Gradishar, W.J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology, 21, 1431-1439.
6. Cunningham, R.S. (2003). Anemia in the oncology patient: Cognitive function and cancer. Cancer Nursing, 26(6, Suppl.), 38S-42S.
7. Desoize, B., & Madoulet, C. (2002). Particular aspects of platinum compounds used at present in cancer treatment. Critical Reviews in Oncology and Hematology, 42, 317-325.
8. Ellis, M., Zwaan, F., Hedstrom, U., Poynton, C., Kristensen, J., Jumaa, P., et al. (2003). Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial. Lancet, 361, 275-280.
9. Epelbaum, R., Haim, N., Ben-Shahar, M., Ron, Y, & Cohen, Y (1988). Doseintensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Israel Journal of Medical Sciences, 24, 533-538.
10. Frasci, G. (2002). Treatment of breast cancer with chemotherapy in combination with filgrastim: Approaches to improving therapeutic outcome. Drugs, 62(Suppl. 1). 17-31.
11. Frei, E., III, & Canellos, G.P. (1980). Dose: A critical factor in cancer chemotherapy. American Journal of Medicine, 69, 585-594.
12. Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
13. Harrison, L.B., Shasha, D., & Homel, P. (2002). Prevalence of anemia in cancer patients undergoing radiotherapy: Prognostic significance and treatment. Oncology, 63(Suppl. 2), 11-18.
14. Isaacs, C, Robert, N.J., Bailey, FA., Schuster, M.W., Overmoyer, B., Graham, M., et al. (1997). Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. Journal of Clinical Oncology, 15, 3368-3377.
15. Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
16. Nirenberg, A. (2003). Managing hematologie toxicities: Novel therapies. Cancer Nursing, 26(6, Suppl.), 32S-37S.
17. Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Research, 48(24, Pt. 1), 7067-7071.
18. Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., et al. (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology, 18, 3558-3585.
19. Pettengell, R., Gurney, H., Radford, J.A., Deakin, D.P., James, R., Wilkinson, P.M., et al. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood, 80, 1430-1436.
20. Rodgers, S.M., Cella, D., Chanan-Khan, A., Cleeland, C., Coccia, P.F., Demetri, G.D., et al. (2005). Cancer and treatment-related anemia. Retrieved December 1, 2003, from http://www.nccn.org/professionals/ physician_gls/PDF/anemia.pdf
21. Schiffer, C.A., Andersen, K.C., Bennett, C.L., Bernstein, S., Elting, L.S., Goldsmith, M., et al. (2001). Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1519-1538.
22. Tepler, I., Elias, L., Smith, J.W., II, Hussein, M., Rosen, G., Chang, A.Y., et al. (1996). A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 87, 3607-3614.